151. THE QUEST FOR CUSTOM CURES.
- Author
-
Simons, John
- Subjects
MEDICAL innovations ,TECHNOLOGICAL innovations in the pharmaceutical industry ,GENETIC engineering ,THERAPEUTICS research ,BIOTECHNOLOGY ,CLINICAL drug trials - Abstract
The article examines the use of genetically engineered medication. Drugs like Herceptin, specifically tailored for a segment of sufferers who share genetic similarities, are poised to change the world of medicine--and the business of making drugs. Many big firms are also employing biotechs, such as Genaissance Pharmaceuticals of New Haven, to identify patients who will benefit from drugs that failed as remedies for broader populations, a process known as drug rescue. In March the FDA established a framework for reviewing and approving genetically prescribed drugs: It released a long-awaited set of guidelines governing how and when it is appropriate for drug companies to submit genetic data about clinical-trial patients as part of an application for new-drug approval. And in the aftermath of Merck's Vioxx recall and the FDA's recent request that Pfizer stop selling Bextra, drug safety is under more intense scrutiny too. As baby-boomers encounter the depredations of old age--especially boomers stricken with cancer and other hard-to-treat ailments like Alzheimer's and heart disease--they are clamoring for innovative treatments. Of course, as with any new technology, the promise of miracles can lead to inflated expectations, and even abuse and fraud. Clearly this is an area where fantasies about future possibilities will outstrip reality for some time to come.
- Published
- 2005